Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + leucovorin + fluorouracil + oxaliplatin
- Development stage
- Phase 3
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ivonescimab plus leucovorin, fluorouracil, and oxaliplatin is an investigational combination regimen consisting of the novel bispecific antibody ivonescimab and the standard mFOLFOX6 chemotherapy regimen. Ivonescimab is a first-in-class tetrameric bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), combining immunotherapy with anti-angiogenesis. The chemotherapy backbone consists of oxaliplatin (a platinum-based DNA-crosslinking agent), fluorouracil (a thymidylate synthase inhibitor), and leucovorin (calcium folinate, a folate analog that enhances fluorouracil's efficacy). This combination is primarily being developed by Summit Therapeutics and Akeso for the first-line treatment of patients with unresectable or metastatic colorectal cancer (mCRC), and is currently being evaluated in the global Phase III HARMONi-GI3 trial.
- Other names
- ivonescimab + FOLFOXivonescimab + mFOLFOX6ivonescimab + oxaliplatin + fluorouracil + leucovorinivonescimab + oxaliplatin + fluorouracil + leucovorin calciumivonescimab plus FOLFOXivonescimab plus mFOLFOX6
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + leucovorin + fluorouracil + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + leucovorin + fluorouracil + oxaliplatin.